This is in line with our previous results in gastric cancer, where we showed that CIP2A expression associates with reduced survival in the subgroups of small tumours and p53-immunopositive tumours (Khanna et al, 2009), and in tongue cancer, where we demonstrated that CIP2A serves as an independent marker of reduced survival (Böckelman et al, 2011). Here, CIP2A is linked to gastric cancer.